Paul Hastings Represents Sciele Pharma in its Acquisition by Shionogi

September 02, 2008

Atlanta, GA (September 2, 2008) Paul, Hastings, Janofsky & Walker LLP, a leading international law firm, announced today that it represented Sciele Pharma, Inc., a U.S.-based pharmaceutical company, in its agreement to be acquired by Japanese pharmaceutical manufacturer Shionogi & Co., Ltd.

Under the terms of the merger agreement, Shionogi will acquire all the outstanding shares of Scieles common stock at a price of $31 per share, for a total equity purchase price of approximately $1.1 billion and total purchase price of approximately $1.4 billion.

Atlanta partner Tinley Anderson led the Paul Hastings team, which included associates Michael Greene and Clare Arguedas.

About Sciele Pharma: Sciele Pharma, Inc., is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular, Diabetes, Women's Health and Pediatrics. Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 900 people.

Paul, Hastings, Janofsky & Walker LLP, founded in 1951, is a leading international law firm with over 1,200 attorneys in 18 offices. The firm serves a diverse client base including many of the leading global financial institutions and Fortune 500 companies and offers deep capabilities in capital markets, finance and restructuring, intellectual property, international arbitration and dispute resolution, investment management, labor and employment, mergers and acquisitions, private equity, product liability, project finance, real estate, securities litigation and tax advisory services. For additional information, please visit our website at www.paulhastings.com.